These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21468948)

  • 1. Biomarker validation in blood specimens by selected reaction monitoring mass spectrometry of N-glycosites.
    Ossola R; Schiess R; Picotti P; Rinner O; Reiter L; Aebersold R
    Methods Mol Biol; 2011; 728():179-94. PubMed ID: 21468948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.
    Lopez MF; Kuppusamy R; Sarracino DA; Prakash A; Athanas M; Krastins B; Rezai T; Sutton JN; Peterman S; Nicolaides K
    J Proteome Res; 2011 Jan; 10(1):133-42. PubMed ID: 20499897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies.
    Randall SA; McKay MJ; Baker MS; Molloy MP
    Proteomics; 2010 May; 10(10):2050-6. PubMed ID: 20209509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display.
    Tammen H; Schulte I; Hess R; Menzel C; Kellmann M; Mohring T; Schulz-Knappe P
    Proteomics; 2005 Aug; 5(13):3414-22. PubMed ID: 16038021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.
    Elschenbroich S; Kislinger T
    Mol Biosyst; 2011 Feb; 7(2):292-303. PubMed ID: 20976349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis.
    Chiu CL; Randall S; Molloy MP
    Bioanalysis; 2009 Jul; 1(4):847-55. PubMed ID: 21083142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative measurements of N-linked glycoproteins in human plasma by SWATH-MS.
    Liu Y; Hüttenhain R; Surinova S; Gillet LC; Mouritsen J; Brunner R; Navarro P; Aebersold R
    Proteomics; 2013 Apr; 13(8):1247-56. PubMed ID: 23322582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker discovery from body fluids using mass spectrometry.
    Villar-Garea A; Griese M; Imhof A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 849(1-2):105-14. PubMed ID: 17097359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma-derived microparticles for biomarker discovery.
    Smalley DM; Ley K
    Clin Lab; 2008; 54(3-4):67-79. PubMed ID: 18630736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying selected reaction monitoring to targeted proteomics.
    Calvo E; Camafeita E; Fernández-Gutiérrez B; López JA
    Expert Rev Proteomics; 2011 Apr; 8(2):165-73. PubMed ID: 21501010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.
    Rifai N; Gillette MA; Carr SA
    Nat Biotechnol; 2006 Aug; 24(8):971-83. PubMed ID: 16900146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotope-differentiated binding energy shift tags (IDBEST) for improved targeted biomarker discovery and validation.
    Hall MP; Schneider LV
    Expert Rev Proteomics; 2004 Dec; 1(4):421-31. PubMed ID: 15966839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the development of plasma protein biomarkers.
    Surinova S; Schiess R; Hüttenhain R; Cerciello F; Wollscheid B; Aebersold R
    J Proteome Res; 2011 Jan; 10(1):5-16. PubMed ID: 21142170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Label-free mass spectrometry-based proteomics for biomarker discovery and validation.
    Pham TV; Piersma SR; Oudgenoeg G; Jimenez CR
    Expert Rev Mol Diagn; 2012 May; 12(4):343-59. PubMed ID: 22616700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.
    West-Nørager M; Kelstrup CD; Schou C; Høgdall EV; Høgdall CK; Heegaard NH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):30-7. PubMed ID: 17112795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data.
    Haab BB; Geierstanger BH; Michailidis G; Vitzthum F; Forrester S; Okon R; Saviranta P; Brinker A; Sorette M; Perlee L; Suresh S; Drwal G; Adkins JN; Omenn GS
    Proteomics; 2005 Aug; 5(13):3278-91. PubMed ID: 16038022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.
    Krisp C; Randall SA; McKay MJ; Molloy MP
    Proteomics Clin Appl; 2012 Jan; 6(1-2):42-59. PubMed ID: 22213646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted proteomics in biomarker validation: detection and quantification of proteins using a multi-dimensional peptide separation strategy.
    Immler D; Greven S; Reinemer P
    Proteomics; 2006 May; 6(10):2947-58. PubMed ID: 16619308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers.
    Ackermann BL; Berna MJ
    Expert Rev Proteomics; 2007 Apr; 4(2):175-86. PubMed ID: 17425454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders.
    Reis-de-Oliveira G; Garcia S; Guest PC; Cassoli JS; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():213-218. PubMed ID: 28353238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.